|
🐜
|
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
16 auth.
A. Llombart-Cussac,
J. Cortés,
L. Paré,
P. Galván,
B. Bermejo,
N. Martínez,
M. Vidal,
S. Pernas,
R. López,
M. Muñoz,
...
P. Nuciforo,
S. Morales,
Mafalda Oliveira,
L. de la Peña,
A. Peláez,
A. Prat
|
7 |
2017 |
7
🐜
|
|
🐜
|
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
39 auth.
Marta Castroviejo-Bermejo,
C. Cruz,
A. Llop-Guevara,
S. Gutiérrez‐Enríquez,
Mandy Ducy,
Y. Ibrahim,
Albert Gris-Oliver,
B. Pellegrino,
A. Bruna,
M. Guzman,
O. Rodríguez,
J. Grueso,
S. Bonache,
A. Moles‐Fernández,
G. Villacampa,
...
C. Viaplana,
P. Gómez,
M. Vidal,
V. Peg,
X. Serres-Créixams,
G. Dellaire,
J. Simard,
P. Nuciforo,
I. Rubio,
R. Dienstmann,
J. Barrett,
C. Caldas,
J. Baselga,
C. Saura,
J. Cortés,
O. Deas,
J. Jonkers,
J. Masson,
S. Cairo,
J. Judde,
M. O’Connor,
O. Díez,
J. Balmaña,
V. Serra
|
7 |
2018 |
7
🐜
|
|
🐜
|
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
17 auth.
A. Prat,
P. Galván,
B. Jímenez,
Wesley Buckingham,
H. A. Jeiranian,
C. Schaper,
M. Vidal,
M. Álvarez,
S. Díaz,
C. Ellis,
...
P. Nuciforo,
S. Ferree,
N. Ribelles,
B. Adamo,
S. Ramón y. Cajal,
V. Peg,
E. Alba
|
6 |
2015 |
6
🐜
|
|
🐢
|
Beyond taxanes: the next generation of microtubule-targeting agents
J. Cortés,
M. Vidal
|
5 |
2011 |
5
🐢
|
|
🐜
|
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
28 auth.
M. Bellet,
F. Ahmad,
R. Villanueva,
C. Valdivia,
J. Palomino-Doza,
A. Ruiz,
X. Gonzàlez,
E. Adrover,
A. Azaro,
Maria Valls-Margarit,
J. Parra,
J. Aguilar,
M. Vidal,
A. Martín,
J. Gavilá,
...
S. Escrivá-de-Romaní,
A. Perelló,
C. Hernando,
A. Lahuerta,
P. Zamora,
V. Reyes,
María Alcalde,
Helena Masanas,
P. Céliz,
I. Ruíz,
M. Gil,
M. Seguí,
L. de la Peña
|
5 |
2019 |
5
🐜
|
|
🐜
|
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
20 auth.
B. Pistilli,
H. Wildiers,
E. Hamilton,
A. Ferreira,
F. Dalenc,
M. Vidal,
J. Gavilá,
A. Gonçalves,
C. Murias,
M. Mouret-Reynier,
...
J. Canon,
F. Bazán,
S. Ladoire,
L. Sirulnik,
M. Békradda,
K. Bol,
V. Stalbovskaya,
A. Murat,
J. Ford,
F. Bidard
|
4 |
2020 |
4
🐜
|
|
🐜
|
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
33 auth.
Aranzazu Fernand ez-Martinez,
T. Pascual,
G. Perrone,
S. Morales,
J. de la Haba,
M. Gonzalez-Rivera,
P. Galván,
F. Zalfa,
Michela Amato,
L. González,
M. Prats,
F. Rojo,
L. Manso,
L. Paré,
I. Alonso,
...
J. Albanell,
A. Vivancos,
Antonio González,
J. Matito,
S. González,
P. Fernandez,
B. Adamo,
M. Muñoz,
Margarita Viladot,
C. Font,
F. Aya,
M. Vidal,
R. Caballero,
E. Carrasco,
V. Altomare,
G. Tonini,
A. Prat,
Miguel Martín
|
4 |
2017 |
4
🐜
|
|
🐜
|
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
27 auth.
J. Salvador Bofill,
Fernando Moreno Antón,
C. R. Rodríguez Sánchez,
E. Galve Calvo,
C. Hernando Melia,
E. C. Ciruelos Gil,
M. Vidal,
B. Jiménez-Rodríguez,
L. de la Cruz Merino,
Noelia Martinez Jañez,
R. Villanueva Vázquez,
Ruben de Toro Salas,
A. Antón Torres,
Isabel Manuela Alvarez Lopez,
Joaquín Gavilá Gregori,
...
Vanesa Quiroga Garcia,
Elena Vicente Rubio,
J. R. De la Haba-Rodríguez,
S. González-Santiago,
N. Díaz Fernández,
A. Barnadas Molins,
Blanca Cantos Sánchez de Ibargüen,
J. I. Delgado Mingorance,
M. Bellet Ezquerra,
Sonia de Casa,
Asuncion Gimeno,
Miguel Martín
|
2 |
2022 |
2
🐜
|
|
🐜
|
Magnetic Resonance Imaging Assessment of Radial scars/complex Sclerosing Lesions of the Breast.
9 auth.
X. Bargalló,
B. Ubeda,
S. Ganau,
B. González,
M. Macedo,
I. Alonso,
...
G. Oses,
M. Vidal,
G. Santamaría
|
1 |
2020 |
1
🐜
|
